Health
Dr. Dang on Cardiac Safety With Pertuzumab/Trastuzumab in Early-Stage HER2+ Breast Cancer – OncLive
Chau T. Dang, MD, discusses the safety profile of pertuzumab plus trastuzumab in patients with HER2-positive locally advanced, inflammatory, or early-stage breast…
Chau T. Dang, MD, the Regional Care Network Medical Site Director at Memorial Sloan Kettering Westchester, discusses the safety profile of pertuzumab (Perjeta) plus trastuzumab (Herceptin) in patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer.
The 5-year results from the final analysis of the phase 2 BERENICE trial (NCT02132949), which were presented during the ESMO Breast Cancer Virtual Meeting 2021, showed that in cohort A of the study, in which patients…
-
Business21 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
Noosa News8 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
General22 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
General21 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts